AlprolixTM is an approved drug (FDA (2014))
Compound class:
Peptide or derivative
Comment: AlprolixTM is a recombinant fusion protein combining the peptide for coagulation factor IX with an antibody Fc domain. The presence of the Fc domain increases protein half-life and extends the drug's therapeutic window.
|
| Bioactivity Comments |
| We have not tagged a primary drug target for this factor IX replacement therapy drug. |
